ARTICLE | Clinical News

Celgene falls on Revlimid data

December 7, 2010 1:51 AM UTC

Celgene Corp. (NASDAQ:CELG) fell $4.95 to $55.64 on Monday after media reports of two studies that showed a potential increase in the risk of secondary malignancies in patients receiving multiple myeloma drug Revlimid lenalidomide. The studies were presented at the American Society of Hematology meeting in Orlando. Celgene could not be reached for comment. The stock move translates to a loss in market cap of about $2.3 billion. ...